Systemic levels of MMP2/TIMP2 and cardiovascular risk in CAPD patients

Nephron Clin Pract. 2010;115(4):c251-8. doi: 10.1159/000313483. Epub 2010 Apr 28.

Abstract

Background/aims: Matrix metalloproteinases (MMPs), their inhibitors (TIMPs), oxidative stress (SOX) and kynurenine (KYN) pathway have been postulated in cardiovascular disease (CVD) progression. We hypothesized the possible association between the MMP/TIMP system, KYNs and CVD prevalence in continuous ambulatory peritoneal dialysis (CAPD) patients.

Methods: We assessed MMP-2, MMP-9, TIMP-1, TIMP-2, KYN and its metabolite - quinolinic acid (QA), and SOX marker - Cu/Zn superoxide dismutase (Cu/Zn SOD) levels in CAPD patients both with and without CVD and healthy controls.

Results: MMP-2, TIMP-2, Cu/Zn SOD, KYN and QA were significantly higher in CAPD patients with CVD than in patients without CVD and controls. MMP-2 and TIMP-2 were positively correlated with QA and Cu/Zn SOD levels, and the strong association was between MMP-2 and TIMP-2 levels. Multiple regression analyses identified Cu/Zn SOD, TIMP-2, QA and QA/KYN ratio as the factors independently associated with MMP-2, whereas MMP-2 and Cu/Zn SOD were independent variables affecting TIMP-2 levels.

Conclusions: MMP-2 and TIMP-2 concentrations were higher in CAPD patients with CVD than in patients without CVD and healthy controls. Upregulation of the MMP-2/TIMP-2 system was associated with QA levels and increased oxidative status, suggesting the connection between KYN pathway activation, arterial remodeling and CVD prevalence in uremic patients on CAPD treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers / blood
  • Coronary Artery Disease / blood*
  • Coronary Artery Disease / diagnosis
  • Coronary Artery Disease / etiology*
  • Female
  • Humans
  • Male
  • Matrix Metalloproteinase 2 / blood*
  • Peritoneal Dialysis, Continuous Ambulatory / adverse effects*
  • Reproducibility of Results
  • Risk Assessment / methods
  • Risk Factors
  • Sensitivity and Specificity
  • Tissue Inhibitor of Metalloproteinase-2 / blood*

Substances

  • Biomarkers
  • Tissue Inhibitor of Metalloproteinase-2
  • Matrix Metalloproteinase 2